The HSP90AB1 Knockout 769-P Polyclonal Cells represent a polyclonal population of the human renal cell carcinoma line 769-P harboring CRISPR/Cas9-mediated disruption of the HSP90AB1 gene. This product provides a loss-of-function model to investigate the biological roles of the HSP90AB1-encoded molecular chaperone in a cancer cell context. As a polyclonal knockout pool, it captures a heterogeneous array of editing events at the target locus, enabling robust assessment of HSP90AB1-dependent phenotypes without the clonal bias associated with single-cell-derived lines. The cells serve as a versatile tool for interrogating chaperone biology and signaling networks in clear cell renal cell carcinoma.
The parental 769-P cell line was established from a primary clear cell renal cell carcinoma, a common and aggressive kidney cancer subtype characterized by frequent inactivation of the von Hippel-Lindau (VHL) tumor suppressor and constitutive activation of hypoxia-inducible factor (HIF) pathways. These cells retain key oncogenic features including dysregulated proliferation, survival signaling, and metabolic reprogramming, making them a relevant host for studying HSP90AB1 function. The 769-P background provides a clinically pertinent platform to examine how chaperone disruption intersects with cancer cell hallmarks.
HSP90AB1 encodes the constitutively active beta isoform of heat shock protein 90, a central molecular chaperone that facilitates the folding, stabilization, and activation of a diverse array of client proteins. Its function is tightly regulated by upstream factors such as HSF1, heat shock, and co-chaperones including CDC37 and AHA1. HSP90AB1 directly interacts with co-chaperones like CDC37, HOP, p23, and immunophilins to orchestrate client maturation. Among its critical clients are steroid hormone receptors, kinases (e.g., AKT, RAF, CDK4), and transcription factors (e.g., p53, HIF1??), which are integral to signal transduction and cell cycle progression. Disruption of HSP90AB1 leads to misfolding, ubiquitination, and proteasomal degradation of these clients, thereby attenuating downstream pathways.
In the 769-P clear cell renal carcinoma context, HSP90AB1 knockout is expected to profoundly impact oncogenic signaling networks. Notably, HIF1??, a transcription factor constitutively active in VHL-deficient renal cancers, is an HSP90 client; loss of chaperone function may destabilize HIF1?? and suppress its transcriptional program. Similarly, the AKT and RAF kinases, key effectors of proliferation and survival, require HSP90 for stability. Thus, this knockout model can reveal dependencies on chaperone-mediated protein homeostasis in renal cancer cells and may uncover synthetic lethal interactions with other cellular stress response pathways.
This polyclonal knockout cell population is ideally suited for mechanistic studies in cancer biology, chaperone biology, and drug target validation. Researchers can employ western blotting and RT-qPCR to confirm loss of HSP90AB1 expression and quantify changes in client protein levels. Co-immunoprecipitation assays enable characterization of disrupted chaperone-client complexes, while client protein stability assays using cycloheximide chase can demonstrate accelerated turnover. Functional assays such as apoptosis and proliferation measurements, as well as drug sensitivity profiling with HSP90 inhibitors (e.g., geldanamycin derivatives), provide insights into therapeutic vulnerabilities. For further information, please contact Ascent Research.
